Recent MNKD transcripts
Associated MNKD filings
| Rosabel Alinaya | SVP of IR |
| Michael Castagna | CEO & Director |
| Patrick McCauley | Chief Commercial Officer |
| Steven Binder | CFO |
| David Kendall | CMO |
| Oren Livnat | HC Wainwright |
Ladies and gentlemen, thank you for standing by. Welcome to the MannKind Corporation 2017 Fourth Quarter and Full Year Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded on February 27, 2018. for conclusion the March of available shortly Corporation XX. be the after this will playback MannKind on website And call until
Castagna; ahead VP Chief the Rose Medical Joining Executive Dr. to David Binder; MannKind turn from Rose Officer, sir. I Commercial Chief Alinaya, Alinaya, would and Michael like Senior Chief McCauley; us to Steven Relations. Financial please call Patrick our Officer, over Kendall; go Officer, Investor today Officer, Chief now
for joining that that you, securities on today's this Good will from note thank afternoon, is statements the federal us call. Please could differ meaning these comments call possible and results laws. It of during stated made actual within expectations. include forward-looking the
broadcast, expectations, company the filed contains that securities conference For only factors which the circumstances after obligation statements call. time or the could Michael with over and This as of events information of cause to the Commission date update from refer reflect by exchange reports turn date Mike? to our February this please actual of now under the call revise XX, or I Castagna. and to sensitive differ results Exchange this the undertake Securities call any XXXX. no We XXXX. the accurate will CEO, live of to is to
Thank you, Rose.
and you. I delay agenda. disruption today us through overview, regulatory As go David to highlights finance I walk will I walk best XXXX, look review us a I'll commercial We're up realize Steve through. on we'll back medical going a to for today's manage Binder to overview. and in that that McCauley the to walk want some and there's through will try Pat minimize a slight with the back through give slides joins and Kendall
get join and us. weeks started, David? - for to we firstly, I through, you talk first David a just I'll the I'll about team. now go a why joining to have Dr. MannKind want addition I what been chose before few like? He's minutes to his thank As been Kendall to let tremendous he two
in of was the with put help join and It and Mike to on San answer a relatively requiring space affairs It's continued along here simple and of AFREZZA AFREZZA namely the space development. mind or top his having to with I and directors and diabetes know, international came research global as the years team the be years the well XX at with team. Minnesota the thank past pleasure at MannKind Many very Having the diabetes Mike, will to the to worked for academic experience everyone. of and their University experience spent I Amylin me you that, of pharmaceuticals join to asset support I a leadership to diabetes at Michael have joining I team clinician of in to unique get I and if team coming in Company the board willing know Prior as be center. you, is the truly its diabetes for diabetes. be insulin biotech the in seven research, honor hope President a when what My when group Eli medical and would years. believed you and in diabetes as for at had scientist leadership had unique in diabetes. a and clinical Lilly opportunity asked nearly background his Lilly came as and individuals Vice Diego the welcome
my support career in thanks through obviously all helped me thanks to Mike, So and diabetes. to in you who
talk - you, at time forward our shoulders. great Dave come as and [ph] joining we you go think, Thank for we'll And with I us, definitely
leadership just walk joining and we When restructuring to XXXX, transform built confidence hour. hurt on last morale the recapitalization back organization we and execution increasing look enabled in burn the really should in off where team major growth three, without made year, almost company in continue a the now growing next we you for Number at objectives. The scale Three we through the plan contract over slide eliminated one, internal we same complete. which in able Number in now we've see built compounded and difficult a efficiency The against focus XXXX. to away I manage the sales the remained we Kendall fall, number is our I that with the as expenses. growth need transformational when completely January and our with you to today things completed to of platform cash us our back So AFREZZA. that same been around to on was today, the skeptical best. direction trade because team fast-forward get is you is team says Dr. complete our one set two, us
stages back [ph], them. through I called of So three look been I we've assets
And the infrastructure first to In stage sales built. full and we about upon in XXXX, with million got I of we continue in back survival, we Sanofi stabilized infrastructure cash commercial XXXX, employee the zero when capabilities, arena. build is the The no $XX commercial product established from here, and XXXX, roughly medical here the team. base. when we got integrated our medical limited we I joined affairs In
with a finished to big a That's a expansion infrastructure coming people in and without company really the For over of example, into by 'XX support. year striving were the of early amount new we employees. talent 'XX, significant recruit end XXX of XXX we hired the talent and had
question to as when that base, think talent that but our stable know a or an for is or sustained from the stability this internal as want not about recruitment company that we in here really many Now I whether and long run. stable be XXXX, the in see and about will a I talk we'll us in of we be that our you to perspective, growth. view we're 'XX good now place see people
value early to growth, sustained that of work the fix I and the and all meet did and a Pat, place, we in finished. look deliver We're about the growth plans critical looking on we I'm et to base from multi-daily focus established, that especially come. that execution we deliver the first the talent we the lines X in train several type product but cetera. be where We today. managed important of but I positioning year, STAT think switch, a through injection the our better. our treatment the are When We type I in at tracks based market. will with plans really the for on our we finally, energy I and one, lines payers XXXX, focus that is this directly back in objectives you'll we limiting back I things happy related things because the people public and years keep market. XXXX in half back. half out success sales difficult of of in we rolling earlier know In as and care done sustained this The on had the shareholder our exactly treatment, And got moving not help of we growth we year. market, change focus we on Sanofi, Number year, dollars is up packaging, from with have product align have learned sampling, medical put we're the we're things because sales hear get of targets our X our those now same So forward in advertising. AFREZZA made know did once our to we our second know through a will lack on we'll thing and look consumer of results the only could investment when on several to around to time, very force,
slide. Next
biopharmaceutical I of is with AFREZZA that Study. highlights, knew can STAT the treatment built core get through invested at with around year scalable and was We get are constrained as have last the we've executive importantly, using base, when forefront And successfully that trials into be mean by positioned follow-up on the team resources, to key talent in capabilities we MannKind the imported we CGM the diabetes technology. to and invest and dosing. journey, some we've obvious what what that we always happen isn't an you So we chose we experienced showing and transitioned data, to which integrated most company, now go
type in we to time FDA believe it's We also is about been X, a several demonstrate publications Dr. possible for critical. schedule. range [ph] what's time AFREZZA Kendall other and in couple very is range of coming in meeting titration will important, data around AFREZZA looking getting [indiscernible] QX, as and at do how and out speak A fast and trials believe you dose is
awareness we where technology trials you be potentially that you expands actually and with knowledge but these see this clinical coming information achieve. as to some mining is ADA, at as results we conferences, the new investments these really where us already So of giving AFREZZA. forefront have as other sugar of of as scientific starting these time Several and position you'll transparency control what made can well will trade-offs existing see well data, of our full and out the all our the meal
conference was Treprostinil XXX% FDA, three presentations, a with out multiple [indiscernible] but I program positive choose in where IND it. last we advance believe not there well a to We've recently it momentarily. program, and those calling begin I the a than ago. in Europe multiple But discussions, for we continue had TrepT different our phase slides year in change positive Just to which as were invest Treprostinil chose to in look as week obviously on And did and our phase, as out we update. we is on we're label [indiscernible] were Technosphere interactions AFREZZA had label September, partners we of for the
as advancing flexibility. our dialogue as our And So we with are finally about pipeline. simplified we and well our our financial continued increased capital excited then positive complexity FDA,
over So in term restructured and outstanding at second, you the end, as I near show $XX in will eliminated million a debt. we
the company. what walk me we Let - you recapitalization as the of been talked we've talking about through about
in the [ph] you'll see is growing can started were coming and of $XX know what the of debt, be. second, in as the we We is put into MannKind [ph] was range, And $XX for forward $XXX and bar The in 'XX, in million and in blockbuster back last or that the we look end from Deerfield cleared So in to a green for million million agreement out X million $XX That's runway so convertible XX million, there and million that [indiscernible] it there. a conversion this million X we see I AFREZZA up to with over to to is growing bar it like And what is million be to able looks a are in years middle shaded of you fundamental bars, respectively. debt year, green place which $X.XX we bottom apologize, reduce up Deerfield moved X-year something XXXX. $XX the XXXX. focus this that you'll you $XX see green apologize, past XXXX January pushed on it when with shares to does note year because the second but by bars. didn't for I is XX then 'XX the we've October and across that 'XX, X 'XX, there recent
those so recapitalization remove in this positive speed direction. company forward as to the debt continue been hangs that So move to we to has bumps move it near we and focus inherited, over continue and our that on the a term
been through the will here that's else that's that Deerfield we to to now year the partners included continue turn want Bruce group is everyone over we've complications I'm million I you Mann faced. notice Steve process Binder. to this $XX very the to thank [indiscernible] because last and through to to that You it overcome the step that's & work the to work and And just say recapitalization going continue to and not of we Company, as challenging
afternoon. good Mike, Thanks,
near-term progress on restructuring and of the we our finished enable just sheet us how support investing clearing our AFREZZA runway sustained growth on focus We continue are Mike make in showing our AFREZZA. out to to balance business grow to to recapitalizing sales. to
strengthening reduced equity me know $XX recapitalization business. simplifying use cash Let we our we've raise results raised million how and operating and the in [ph] our in have sheet. to balance review debt, summary, progress, used which to In
And $XX $X.X the depending million and a conversion reduced $XX at million between debt price corresponding of by by time Deerfield. future $XX the interest debt expense million set the have annually. conversions amount and reduced for by We million conversion upon of we've
So sustainability reduce to average the to Deerfield, per raise assuming a upon equity all million which debt the $X.XX depending with We actual future past over we've XX-month translates these completed an company. our convertible debt $XXX million, transactions $XXX of to of for long-term combined equity is share cash using range transactions $X.XX. in and and conversion to to strength and approximately price the totaling equity believe support converted
XX-K read our the within XXXX so were results, of our release. full-year financial filed Both I'll Moving select financial quarter statements fourth highlights contained you condensed and quarter financial as statements discussing which afternoon. be on the in urge consolidated consolidated this press contained our to financial fourth and
relates AFREZZA XXX% volumes, impacted by $X.X product ended X-months cartridges increased distribution more estimate quarter in was revenue XX MannKind estimate revenue data and December in the For sold change price, and for commercially. over favorably XX, the to the channel. XXXX, Net X was increase for the of The regarding net change $X.X the that and adjustment our inventory quarter QX new mix million. fourth which XXXX, comprehensive AFREZZA was our unit obtaining million, favoring in second
estimated less revenue. syndicated in prescription the in we amount previously which channel. in inventory was inventory channel [indiscernible] adjustment the distribution net Specifically using resulted deferred than indicated data, an retail that of to the
revenue. Our gross to of gross full-year adjustments XX% XXXX net were
million As recognize from a XXXX, Research revenues model, development move ship will clinical due QX increased reminder recognize AFREZZA in to direct where a revenue to sell-through of a not we'll when product XXXX, cost trial recognition, and million XXX% we're wholesalers. on $X.X bought revenue a Beginning in shipped we for we wholesalers. increased XXXX, sell is a primarily customers $X.X the in to pharmacy, we model when the and activity patient like in from the in later XX% of trial program in the of quarter support ramping due after primarily about an will in agreement. $XX.X discussion. CMO SG&A Please Sanofi the the our in in expenses AFREZZA XXXX. recall to our commercial the million David our of QX that integrated up Kendall, over over for XXXX. new structure in speaking commercial were be fourth clinical our investments XXXX, investment mid-XXXX, XXXX, we took began commercial increase termination to
advertising $X in speak in our QX our television the addition, we XX one to country. our where In XXXX, investment in Chief the had later Officer, markets of McCauley, across invested Pat million direct-to-consumer Commercial will test we of campaign call. commercial this
the commencement year we license agreement. comment Sanofi the on the our of much XX, of mid For I'll XXXX to December activities year only collaboration determination after revenues, that ended net the commercial AFREZZA don't of full XXXX, the is believe starting meaningful comparison and
was we in with winding some year collaboration. during million, to fourth activities the quarter million expected relevant. to in QX year [ph] not organization XXX% related $XX our XXXX net up $X.X we to XXXX, cash AFREZZA of earnings the the we've of activities, our call. XXXX Comparison have impact compared There and XX, net significant operating operating final XXXX, revenue Sanofi, increase and range which The the in was fourth is increase as cash to transactions XXX% is AFREZZA. the a used using from - for the a of for communicated ended integrated sorry quarter in investments net prescriptions $X.X made December XXXX for in fourth quarter increases effective corresponding XXXX, commercial million So
a second financing guidance $X MannKind are second from has discipline falling gross had equivalents choices the registered $XX.X cash flows million, $X.X organization in a Addressing XX, $XX.X we million. for aftermarket inclusive $XX.X revenue estimate spending activities At the December our grow AFREZZA and for XXXX, and from million our tighter of earnings of to million results for Our in half quarter $XX and facility. net common XXXX. change included million shares third is in our to December we to the compared $X.X estimates, an within AFREZZA. for XXXX range AFREZZA of million adjustment In in call, QX of cash versus investing issued August on million, million $X.X around for was direct $X.X developed placement at we making adjustment cash, of updated XXXX, guidance $X.X million. half restricted cash appropriate and revenue for million of of cash inclusive change of XX,
[ph] into XX%. Officer, we XX% call was provide sales of now guidance for impact $X to within which cash to which net the the launched turn I low didn't range shy over McCauley, confirmation operating this the program, June Boucher $XX million impacted Pat? in which the half our gross forecast million. of guidance manage our new to To well. activities our of guidance, just million, for $XX.X XXXX to activities, Although will in favorable XX% continued we our AFREZZA is to and of came to the $XX second end sales approximately amount commercial gross insight that Pat XXXX, cash was The our is achievements, adjustment of at million, to the to gross our plans further Commercial used by range Chief Net in a
of to full sales key February year team as going fourth metrics, are performance with good is our today we transformation excited we back and started XXXX review some the MannKind in one completed, share at our of almost had continue our MannKind. commercial as afternoon, very Steve annual you, you highlights, Thank am Today also to of everybody. promotion. quarter I
as 'XX was the Now upon can building you very, our stated strong established are shifting call, earlier assure that XXXX. that in from in is very indeed and growth 'XX fully phase to is to back one stability Mike foundation committed we I on working team sustained off hard a and the in
success, doubt and is going first of pilot and initiating learned TV did move we're date bit that continue like So about our so forward. in detail commercial and We a days, to sales our prescriptions, in last talk so unit and let's going key grow establish are performers. X seeing by to to grow continue including riders. you're Without finally, look been talk they QX deeper you we volumes, this sales XXXX. also growing our we've hiring at And coming over AFREZZA we're dose how we're individual critical, out across top look since dive XX the in and for as specifically units to quarter these we and continue a sales earning start we'll of we recruiting movement at regional whenever and in is also importantly a at look some only the in what sales, NRx Also own we on assess moment. we taking TRX, our significant highlights. year-over-year sets in top metrics, the the but which what so did to talent wholesalers, positions and just the really are earlier look trying Most and a commercial XX multiple to fourth AFREZZA call, little cartridges not of the in a showing to contributions here the look some about I'd talent at with of share in QX, take in
just we're coming year So MannKind promotion with sales before, off as first full about the mentioned our team. I of
NRx a QX, and that at out XXX%, at year start you metrics XXXX. approximately grew TRx's the growth grew across at let's full of to period about the XX%. for XX% fourth from key take the grew that during quarter, new And the quarter see QX riders look you to from if So look and first will has
an AFREZZA these increased because them clinical important you and experience. they demonstrate providers when number look whole of patients are gaining numbers at Now in really
we I'm one at definitely can as thing rider so the going that stated we look significant However, that's even and at know better Mike new you growth. when earlier, to growth show here, just with do you XX%,
AFREZZA. a forward. number have have this a clearly We great riders also know a to opportunity view plan and call we we moving And potential as of on our large yet prescribe that
see thing market Another we territories have over X% share, less. that acting we've is, territories other while of individual some rapid have got a
across share going just it's with and be important for to example contributions So a of moments this us in some very additional going balanced I'm territories all get to to more few you.
performance. at look our TRx take now Let's fourth a quarter
versus For the grew about quarter fourth XXXX. quarter at prescriptions XX% TRx the of third
about to through that the AFREZZA if I to that You see and some that way moving plans period have And all in decline seasonal can can we briefly during minute these accelerate with but from January typically doubled just also to in December you also the expect in not in take the trends occur look tell I all continue, January TRx pharma perceptions about to over period. forward talk XXXX. of December, just growth we is industry. wanted shift you only the to place, a
insurance coverage, the you see, changes, that as of just deductibles go authorizations of at scripts couple in about side looked this prior one and January this seen diabetes expiration to AFREZZA from we moment, occur On typically other transitioning disease half and will the We X-months well. of to the 'XX, January about a we can we've XXXX. we've the of AFREZZA December believe December in the believe in decline benefit but new not and date over states in is things, changes new half other X% has the of happened decline design just typical a of was 'XX due with reasons chart, of about right-hand vouchers to in our to past the of due
left-hand back chart look one year decline the this period. of about AFREZZA January to an circle, last December at the if XX% in you by ago, red the highlighted reminder, when experienced a year TRx's side looking on As
a to Now already happening time, were that you the are the through of kind our to see we AFREZZA But we just MannKind team. seasonal now transitioning starting effect, sales based to January indications wholesale observations AFREZZA data internal we may we're news the mean growth co-pay in near is recall what's ordering, in the been trajectory in at impact of on recent I And good is good is at looking in returning news that sharing TRx that the a by these card positive with and the trending, the redemptions. retail term. what and expect to see growth
individual Next performance to more we're a look with take you. going little some the to bit shared a of at I shift territory
basis, Now not and you be really top highlight performers what this data this the are of line that the our all the XXXX. is of XX some for purpose territories you'll the see that may on of represents and growth a time, top and our what quarterly that typically representatives What to AFREZZA is we know see of. top capable so on doing our
the and our line national third line top second represents at The average. is the the XX bottom
Now know accelerated we this that representatives experienced and it some top our top of at growth, you that clearly in you'll cases XXX%. of many type over they see closely We performers. see if strong and those territories possible growth performers, is the very look were in
to sales accelerated going and clinical other across to training, we and team sure where and and the and strong in also expect At sales that things XXXX. create we into we to performance we commercial that performance a from messaging, selling being AFREZZA make We're high met. planning our of our needed territories all addressing as and is build we be model believe performance not put that MannKind look that are what leadership are growth going model, drive as place our this low team. investments Although really expectations
to experience and drive come those characteristics also we've first about learn individuals in Another some selling well as great traits training thing the have typically very that are who also as individuals in tended chance they to and high our business about may a top you, we our are no to specific that interesting these about of passionate more recruiting are obviously diabetes effective performers but is and as disease year acumen. success surprise efforts, in AFREZZA this in the well. deep clear and incorporating that had highly messaging, field The into our
start the are MannKind. few So the to take continue at here we're build we higher recruit 'XX, the a now shift just at shift again things these look and of individual X a fourth to to that talent high of not going and AFREZZA that notice when that but just growth look over but you AFREZZA cartridge slide, XX% at unit we've mix to at the And lot and transition mix. our going the as year. units, drill also from our that some XX% change equated to of of continuing the XX cartridges unit at And see the cartridges in seen quarter cartridges. some to first and We're about only quarter down to looking seen to at very we've the XXXX. fourth in volume quarter on down of and the our the information of total the a continue you'll There's grew we're a level,
of is represented value XX%, fourth volume you up volume the about the specifically of at the about XX% very also in the cartridge, XX interesting contribution fourth see the it you'll - increased the from XX% XX% unit at you units, in mix, quarter. which quarter that volume to look that fourth just to if quarter also look fourth If XX that from XX in dollars quarter of unit
packaging the at us all that volume to mix and in made does you for that the mean We will of this continue what the dividends when and believe adjustments So XXXX kind change? pay look we've in beyond.
also We to to achieve our more as glycemic dosing flexibility packaging their for patients that needed indicates provides this control. titrate believe
things some couple I next the an talked with and you for slides, you we've previous wanted calls update. of Now share about give on to
we our evolve first is will to relative clinical a have - how The of and to TV there commercial messaging and about our then comments highlights. one couple continue I
one customers, a And when FDA we've do to lot we market, And listen messaging. of on continue AFREZZA basis the a to since this we've You done know, last things. to listen the it comes that October. to heard and from especially occurred clearly things our field, the is an the our ongoing update label of to feedback continue few
definitely acting in First, healthcare rapid this professionals a clearly our label action PD update is our AFREZZA recent for a PK with physicians. profile key defines profile, believe the for time attribute
Now based with [ph] market and we interesting research as what of and things. well, the segments, know other AFREZZA the and we're customers and been the and daily hearing care the endocrinologists focus from most some on our with We with patients of that physicians interactions primary conduct launch multiple in from injections, they XX% even field selling hear represent has one the about challenging did market.
can approximate XXXX. and was yet providers the options segments. earlier, in of part shared AFREZZA back patients this progressed done payer XX% of had changes patients for individuals and restrictions we who due looking all treatment for for the to [ph] through working are But to that other Mike we the of these in have prandial As not believe that MDIs, control clearly help in these
targeting us research in on well with basal drugs, those patients for as living progression, as the market on a such diabetes insulin. as for overall So their anti-diabetic all roadmap those has earlier disease provided
to we Now valued the perspective look that these highly here of those PCP in already we're other the many good is for today. of targets news and as we offices some segment, and the in start potential are targeting at
with you full some we've captured it X early today a sometimes you program look our want fourth the months say But started pertains let's weeks to the So wanted the of know some to a campaign indications and that that the not only just as and about on that we've the of of of relative call we're regional many weeks at at the shift really specifically to to riders. to the of data to share few early since end take X data as assess I takes I and it feedback least pilot in if impact. TV had quarter. we pilot
times there if non-TV pilot-based TV look and where had new at riders we about First, you a riders in compared to the a growth commercial the X the was markets markets.
TRx's are promotionally responsive. continue these Secondly, the these all to early, a did assess you to times times these shared at things the those to But look are we watch pilots about key unique you and very, or that closely while is the in going markets. what average non-TV is the before overall one average signs at that we're weekly compared TV we and be again riders fully was this think the rate AFREZZA and in when with XX% pilot XX about weekly steps X TV our going of when takeaways next markets, in reinforced to determine is very I the numbers, it's there a there in in growth and All was the growth encouraging, that areas.
growth. TV put the when can AFREZZA know that, we incremental other representatives create In addition you like and combined it we stronger campaign that efforts, things with and to promotional
at So on about in what with positioned about when excited here, for the I very of well to about and growth execution. and laser slides, focused tell a looking we you want are comes wrap couple future on we're up down it just you that more AFREZZA field little the more to why
we the foremost clinical of our this in have safety, also AFREZZA type discussed and data and increases understanding in is experience just not many in of further efficacy, really dose the studies important average market but this for AFREZZA segment, as some messaging. it and we patients first ranges X and So earlier our clinical showing that
also a medical and with in David hear just publication a minute. team from We we're to going plan him have robust and our
when individuals, progression of of also opportunity outcomes. on and at in that some very earlier payer as previous the is of only us of mix of diabetes. need This sure finally calls. means AFREZZA treatment very access are living gives volume the have our very exchanging, we and are X about very, going to efforts better to We've here with I additional the that clarity for launched as Mike coverage, just and and as titration with into to XX these the physicians with need but elevating it's patients And plans for our we're cartridges many Cares as patients and trial an is and make of some unit MannKind to further to know So on highly we more We're our sure available and they have first from talked the talked higher about living those excited reasons at patients to samples, packaging, the create some and this about I've that talked look begin know not is initiation the We increased that we forward relates that it AFREZZA, cartridges unit which we've deeper the best we patients need, focused of what diabetes. individualized also consistent titration for packaging initial diabetes. we updated both AFREZZA. this support the make include efficiency successfully on patients shared,
put in 'XX at sense share looking give very plans, want is do efficient So lot consistent Execution couple XXXX clear a we're that what of you know of in everything we we in manner I just for into creating It people XXXX is a of these and cetera. be that at. place. plans all the as et you the wrap to spent very very, to in I the a right we against center us. I putting with that examples will execution a up, strong and of places, about time
our am Kendall, as with though commercial, us making strong alignment appropriate very closely especially one working even most David value is to few things in of across I including all think just has and the our be I've progress the pleased align we past medical. months proposition and over cross we're opportunities departments, I payers and joined functionally new a area. noticed to work recently, Chief AFREZZA been the this know across have identify I of Medical we that David clinical messaging Officer lot MannKind. There important alignment
we when the you I we think of sales it, another key about messaging force. comes lot we've a talked to clinical area think is that about. things it without done our And us doubt We've there. when for to promotional execution improved a We've evolved excelling territories continue representatives call capacity. territory each materials. in these adjusting their By and further help refined created will even We've Endo and we've more customer plans our for new and reach. areas, reach maximum full PCP
managers as deeper in regions the of the time, that We've this cost educators. and couple us I'm the trade-offs I'm cost territory the a us growth working talked that also out have 'XX, And structure. provides program been forward. to continue as differences director, reporting that company with recently. going lot some that's And car be to hired a has do, in involve rolled the into we national as this into directly about will announce of highlight just very you an streamlined a individual that success decisions go and we're to shifting the sales always going deeper savings, to we've I we national as as year-over-year to for some investments same So only heavy, execution, our to but a not of excited focus a report structure things to look we success to we've also sustainable experience well performance future And people position that make front-line in At the us it to nurse going for heavy investment know for as as level. focus director. and sales moving development. relates for in and this best
a investment decisions these and again, continue trade-offs, going just and the of as highlight these into very, looking we're we at XXXX. are closely few through move very but So [ph] to and
had in productive and fourth want team. We closing, that things better. proud of do XXXX. share quarter great we're we believe with the just move positioned on I very So year the was 'XX. right in I know really people We we the right you the well into to plan and very a with place. right in can focused as We're for future growth a I
other I'll Kendall. call is continue the with to that the drive The efforts Medical Officer just commercial our hard been of very doing proud to At our and we turn I for the momentum and comment, Chief I they've am over work David time, thing all thank AFREZZA. team success this to wanted as
evening Thank the research follow on described as I or truly again you Steve comment, And all and did who've across Mike pleasure call this medical and appreciate you is clinical to early affairs activities. the afternoon, a review It join team very much, to joined thanks development late and U.S. afternoon Pat. our coordinated financials a the leadership Pat effort just openings between scientific this
and measures as to the continuous the disruption those establish X for and with glucose both hypoglycemia to to priorities and establish diabetes. of a individuals executed provide time focus with have are that glucose the to diabetes shown regulatory we referred the to to screen, was by measure assure requiring safety development, assure additional about the time were earlier, we is As before make on clinical living that accepting to patient our a that evidence of and that as my in I assure the but caused a continue a improvements and in for activities want of measured those, living measurements Mike not have treatment experience part use management responsibility insulin and elements on serves that that for range, We and improvement timely critical the control overall responsibility patients X I we in frequency of appropriate to in I as glucose novel this I the and will and disease, fashion look but being few of of diabetes those treatment only type flash details feel we the moments, into in detail type that job to glucose control experience treatment. number established dive monitoring, in satisfaction meal with by with it the including the just effective, best of clear end-user very medical and fashion patient patients coordinated support AFREZZA clinical those safe, research, need
regulatory very these research, priorities are all group are we X have clinical, straightforward for our medical those To medical safety for defined and endpoints. and the groups do So so XXXX focused here. listed on
scientific The and and to platform assure data there is of development clinical to lien and awareness the clinical the the communication the of AFREZZA. support of first refine the use plan enhance is scientific to execute and implications that clinical
We XX moment, that is just a of leverage part time disclosure this that a through AFREZZA existing studies review a plant and on data believe outline glucose are AFREZZA on execute to evidence the These also the Technosphere and and inform research we of and plan based existing will been of diabetes control help and only will pieces meal but can comprehensive plan. diabetes not with executed more robust that a of clinical their importance those of the data. development patients as I'll use community sets, than clinical scientific a our do have with insulin treatment
to that is of assure to is in consistent and of is done forth all information strategy positioning in AFREZZA, AFREZZA we and for of outlined. further that of that that for a availability is with the regulatory that for will plans commercial optimized support specific put the clinicians Pat assure a and Finally refine patients labeling this fashion implement set just
in and us AFREZZA provide where of that AFREZZA the beyond. a full the the help development Phase detail in Phase pediatric we the purple here clinical of patients priorities the clinical II inform those program. to pharmacokinetic of ongoing top Now will use on a for is actively III come at the figure are with I and commitments XXXX have summary day population. provided that will on better be specific which Namely XXth for here in program XXXX study, this program, portion pediatric from application regulatory into you my some programs with the additional Shown stand our moving MannKind enrolling
long-term a of of the the AFREZZA that have and plan performed first discussions and about in of insulin fashion are the In with initiated will regulatory safety our study, be that XXXX addition, AFREZZA study moving available currently inhaled negotiations the to discussions a clinicians requirement part is best informs part assure authorities the only clinical and that that in long-term be will XXXX of will development and use and consumer forward. in safety
originally study compete and will insulin. with, in patients help This acting diabetes. improve already not budgeted treated insulin but of AFREZZA for identified has for to both with is Mike mentioned, only data, the commitment will actually additional including in to meal the potential rapid this, information that is for looking dynamic post-meal in AFREZZA upon to programs XXXX was detail and blood add and addition at to currently clinical [ph] glucose time solidify dozing In ADD-X, that study a development so-called modeling control dosing encyclical us the paradigm
specified this in spends at been glucose range. has This scientific measurements, patient blood of have completed for In addition presentation year's a leveraged glucose namely continuous the looks if ADA review completed or acceptable hopeful the the been meal technologies already monitoring to how time AXC technologies, STAT glucose obtain control at that study to can and be measures new recently glucose this namely those glucose submitted amount study of and Mike hemoglobin new self-monitored time beyond referred has and to scientific for data sessions.
In highlighted study performed an has meal by dozing as investigator an loop continuous pump uncontrolled a investigator Drop at with addition, ongoing current time initiated diabetes the to X technologies, AFREZZA in University area. collaboratively is patients we've program been group tied glucose use system Yale use the being application of study with initiated, done comparing in And an pediatrics to finally hybrid monitoring. closed Baltimore type the One other such
of as requiring the program the time use this of is this off support control effective while standard of dozing meal patients believe AFREZZA improvements glycemia. clinical meal glucose time in So lean and in provides additional potential we for care application that essential efficient, element the will and
hypertension his will the key to submission that be and program that Technosphere This proximal called XXX(b)(X) introduction. executed XX-months is [ph] planned platform, over of and next Treprostinil initiated outlined uses here. the program like pulmonary Mike arterial Finally, I'd highlight in one the additional the of which documents submission is are discussed in development accumulation that program before
system. clinical for the nebulizer As those looking only previous was was available a safety at press through this here of January currently delivery available at ascending initiated be higher not in quarter Technosphere the looking doses within the noted outlined system third anticipate will we of and anticipate submitted dose completed delivery and delivery information delivery of study This by anticipate as first currently the middle in we quarter doses, IMB year. initiation an but by we than of [ph] year Treprostinil this single
limited allow requirements XXX(b)(X) platform. switch an to and Technosphere outcomes the a reported options pivotal the program the us or tolerability study pharmacokinetic study. Treprostinil efficient the the include through that treatment given and patient Thereafter to Both which of tolerability, current pathway, number, from delivery of the assess safety, but Treprostinil efficacy of of number patients the will delivered
is as space medical as diabetes Medical the of beyond first for my interest and something care MannKind in space. and join regulatory who Chief So of of opportunity the Mike, XX-days progress some development into XXXX again of programs this will to at research, medical leadership the all gives MannKind in Officer experience to the XX in you in my you thank clinical both entity and MannKind I highlight have insight clinical Directors that AFREZZA want and the years to once the and I Board the an team safety and hope leverage
all XXth year insulin's I like as and it product. of remind turn I'd the close So this is listening that a clinical to as to availability commercial Mike, back those
development establish I've AFREZZA control AFREZZA's in clinical of and today. programs time insulin in the that vast namely also the space, mechanism another route the but to for meal majority glucose XXXX outlined we opportunity the place paradigm to clinical the delivery pulmonary have introduced unique of insulin perspective, has alternative that scientific and been shift a and utilizing meal subcutaneous from route, the with the via delivered time, time feel First I the
that team to So with I'll to Mike for summary you the and turn back and and you thanks it conclusions.
Okay.
thank the that Today to David, kind back here. with So wanted come you, Pat of I to slide and opened up Steve.
something that a novel So is when you look therapy AFREZZA different. truly back does
launches one to which things two treasure a is technology continue little to at a all by need see higher control. XXXX look people are trial started because look a believe we follow These When baseline demonstrating trade-off what and there we really by better type see invest continue back meal In diabetes invest are is more unmet data evidenced what doses one main in However, half at made we've for of for of versus our missing for drug under titration less like how people [ph] then AFREZZA. make we try year AFREZZA. about see did strong does and [indiscernible] time is hire try these there X, back these ago that dose is change will data one our could research over AFREZZA Levin of dosing or and when we we and than the much XX the happen, finally upfront, showed you to and this took and data and significant program have the given much STAT that have it's dose to the individual weeks second show think we're starts need believe type market that our customers dose will recently study. that the conversion important public We add done reasons what you was schedule the XX to our and where didn't the we get in we is through appropriate done, were more generate up going showed believe higher trial qualitative know along story sustained of lock what when and possible patients really and area connect. will it for get - we trials. ultimately to demonstrate a messages move continue decide with development What We things years. confident XX growth. trials direction new [indiscernible] we with right the we beginning clinical is with them down. that sacrifice dose these as and clinical where X a the in the these a we've in people to outcomes X when This understand clearly completed you back be in our a in that insights they titration We direct giving were to to and of the two modeling what appropriate new we really and we dose data confidence our trials, control end provide I trials. back reps we to probably is in will finally tested real-time in the to adopted we dose to I'm adopt to look today people
is and make order have of XX job it not growth our see insights it's call those to to in to hundreds market what As conducted today, of we drive our along Pat territories. of AFREZZA, can growth top our customers job understand drive translate reps possible. hand, first significant is tried you our the research all showed with recently across and out X the sure
our track. and So slide you've there to launch Brazil XXXX. with on to about We've be what next seen talks expect as And we I earliest is partner markets wanted coming QX having been interactions remains this international say which able as to up. positive
and we're have the in term sheet we a a large a the Additionally, finalizing sheet. term of U.S. process fine outside second market for
go next here sustained rolled delivered we for out which and you've markets. that company a originally The of while is growth the slide earlier in in difference other We - year, first and will both is of the know these start markets we September, times to more expect us as while serve while but need of things generate will to patients recently hope AFREZZA provide the these seen you couple cash, to difference have will U.S. purchase allow have in hurdles formulary away, the know events. signed large at structures is Blue a to million continue the we a We for upfront do of combination continue updates which manufacturing want deal CBS, to plant royalties people's give and key milestone so take share some couple been term a society, of have to now waiting know, queue client, not lives. in a commitment that the to markets, right I One few us the of a end, a minor California on markets space. In a a world on. some people those XX I of to the and enables announce people payer offset these we time. have to Number downstream will who near maintain tremendous together in I this around like remove a continue milestones a make and they in it's that a patients the we up we to and million to continue lot will these national Shield these AIC and managed-care believe these XX of and importantly we may plans around just contract added not their tremendously with and that to with we XXX of segments these, have Hawaii, will the one, have coverage. [ph] increased in go
cash the took announce a over program and co- some better able to We be a exciting upside program, last in shortly as we for topic bring think right patients just people I We're are promote AFREZZA looking Another and is grow for time. better but opportunity, the is as that's hope be will much to model is One know see out the that internally a diversify get and In the another base full moving years. still year, we It's this Drop. to haven't we what next see is it our about have and direction. opportunity. we for talked a we expand shareholders grow assets X Should X end and or in co-promote more an our partner it to the in revenue faster, take look to that always I to look to way. novel
continue for what the will thing believe shareholders. to best our monitor We identify we is and
touch to guidance. want I Now on XXXX
we operating January XXXX to and full-year of of net $XX $XX million million remind cash $XXX guidance cash. Our million that I started with to will $XX used you net million. X, $XX in approximately revenue million revenue in is activities
to believe believe bring fund through international are for on very QX. the also of pipeline base opportunities deal we and about to continue company. come numerous the minimum continue million expansion international it's go long-term well as really our the the adequate sales conveyance like driver growth to the to what job as product of assets. our And on We as reason market. grow on well we of clearing of the and U.S. and of prandial roadblocks revenue, to fine AFREZZA most what we as bring to AFREZZA AFREZZA or excited are matter to see available so recapitalization looks the the control potential hard you as sources work and there, and company co-promote ATM, along. as and done you drug continue end the equity finally, you $XX propriety There debt view We've of a [ph] a what our transformation is we profits be continue the have to continue company will believe to for with need we in sources AFREZZA gold build the a our still at partner. to bottom. [ph] We're can it standard the in the be. we see great successful and make show for that here partners launch, to hard in continue we We base could in we partnerships U.S this look as get can licensing, be capitals company, to out, There so the XX% of from here. will the we increase We we it
unmet can need some seen that and adopt in You've serve differentiation Treprostinil, an that believe market. we
that to be We we a And Phase in-license in new diversify can AFREZZA we'll in population III to another look label demonstrate revenue finally continue base. continue a to opportunities what a trial believe our and pediatric ready. will then ultimately for do with program also bring area serve
had for the long to this in our their we thank we'll five team it's transformation over but to and moving and is that the patience, and view Thank hard to I'm very expectations. and continue direction, think short have work for to been we this compound focus exceed can will want you I hopefully Q&A. know shareholders our meet future. generate the deliver a right journey, and So growth ever forward best that this continue everyone I've re-capitalization term are energy to I we open I we look to why all looking you on next the we years in of the so so our for
Instructions] question Livnat go from ahead. Wainwright. And Oren a you. have Thank from [Operator Please we HC
you Can Hi. hear me?
you. hear We
are yet script you guidance? mid-February, Thanks. just on trends specifically near term get little do so seen to hit can relatively I you accelerate what bit that confidence can data IMS so are be an seeing, a talked shocking your about taking call great. more wholesaler talk Hi, seasonal that January, questions. Earlier don't we to the for we you back. churn you all going the of track through think very most in an you're which can the already guys indicates and in after a co-pay redemptions not sort I or bounce seeing some about seeing patterns ordering of Thanks get you acceleration - you're the recently guess early we
Sure.
think good I So it's a question.
We severe, think XXXX half XXXX other vouchers will decline that the going as was the lack does show market the see. going morning half able Pat driven for or wholesale by we be you Monday more wasn't things that XXXX by of What not gives the I to that two us of orders The a renewals typical every confidence we see driven week. see. was see is, XXXX. and into into previous
what We from shipped wholesalers, pharmacies out what down an drawn indicator which is year. have the of the also previous they see
weeks not to of back in those we trend were if All December very are last we cases. and some have higher indicators where to positive continued over in three
we're to else feel we going anything see good what seen. here nothing worst So we've generally that lift, is that beyond and us think indicating terms there's I in behind that of
couple general take and a view that bit XXXX is of sales the rolling accelerate marketing for our little a I we out. a meeting, will to with of pattern of We will growth we have hope the in days to - noise world around nice we're success continue that, tools new force be a get kind for think sales you may of but
Great.
new does the had in that guidance, I that we going can but tools, about see guess, spent we or million, where term think burn mostly to talked obviously you you keep expect didn't marketing just you are QX. –you near So I guess go back about SG&A trend investing I the pilot SG&A, question, the to all you in talk year give should I cash guess should that money in DTC $X program elsewhere? that full
No.
can DTC. indicators I I lag we will DTC, measure some in once early takes really know we that obviously think prudent, some keep saw and we $XX see we to think the to effect sold positive. we But be are measure that wanted investing in sales, we million time just that of and
recapitalization phasing But that giving as to we extra I million point, we're perspective. and not update And decide investment DTC expect from those so we'll think to spent can we I us on make guidance don't think that trade-offs in company the make. through a you quarterly of probably the QX communicate are at we'll this if go spend on but $X
for now you joining, Ladies disconnect. and Thank gentlemen may concludes this today's conference. you
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.